Oncotelic Therapeutics EPS - Earnings per Share 2006-2021 | OTLC

Oncotelic Therapeutics eps - earnings per share from 2006 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Oncotelic Therapeutics Annual EPS
2020 $-0.11
2019 $-0.11
2018 $-0.12
2017 $-0.52
2016 $-0.51
2015 $-0.54
2014 $-0.75
2013 $-4.67
2012 $-5.48
2011 $-10.37
2010 $-71.60
2009 $-158.46
2008 $-168.07
2007 $-175.27
2006 $-134.45
2005 $-146.46
Oncotelic Therapeutics Quarterly EPS
2021-06-30 $-0.01
2021-03-31 $-0.03
2020-12-31 $-0.05
2020-09-30 $-0.02
2020-06-30 $0.01
2020-03-31 $-0.05
2019-12-31 $0.06
2019-09-30 $-0.01
2019-06-30 $-0.02
2019-03-31 $-0.14
2018-12-31 $-0.02
2018-09-30 $-0.04
2018-06-30 $-0.03
2018-03-31 $-0.03
2017-12-31 $-0.09
2017-09-30 $-0.13
2017-06-30 $-0.15
2017-03-31 $-0.15
2016-12-31 $-0.12
2016-09-30 $-0.12
2016-06-30 $-0.14
2016-03-31 $-0.13
2015-12-31 $-0.14
2015-09-30 $-0.14
2015-06-30 $-0.13
2015-03-31 $-0.13
2014-12-31 $-0.06
2014-09-30 $-0.17
2014-06-30 $-0.23
2014-03-31 $-0.29
2013-12-31 $0.04
2013-09-30 $-1.88
2013-06-30 $-1.86
2013-03-31 $-0.97
2012-12-31 $-0.92
2012-09-30 $-1.56
2012-06-30 $-1.65
2012-03-31 $-1.44
2011-12-31 $-1.44
2011-09-30 $-3.00
2011-06-30 $-3.84
2011-03-31 $-1.56
2010-12-31 $-67.95
2010-09-30 $-40.82
2010-06-30 $9.60
2010-03-31 $-40.82
2009-12-31 $-28.81
2009-09-30 $-67.23
2009-06-30 $-26.41
2009-03-31 $-28.81
2008-12-31 $-12.01
2008-09-30 $-60.02
2008-06-30 $-60.02
2008-03-31 $-45.62
2007-12-31 $-50.42
2007-09-30 $-45.62
2007-06-30 $-45.62
2007-03-31 $-33.61
2006-12-31 $-28.81
2006-09-30 $-33.61
2006-06-30 $-43.22
2006-03-31 $-28.81
2005-12-31 $-38.42
2005-09-30 $-40.82
2005-06-30 $-36.01
2005-03-31 $-28.81
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.048B $0.002B
Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29